1. Home
  2. NYXH vs NKTR Comparison

NYXH vs NKTR Comparison

Compare NYXH & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NYXH
  • NKTR
  • Stock Information
  • Founded
  • NYXH 2009
  • NKTR 1990
  • Country
  • NYXH Belgium
  • NKTR United States
  • Employees
  • NYXH N/A
  • NKTR N/A
  • Industry
  • NYXH Medical/Dental Instruments
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NYXH Health Care
  • NKTR Health Care
  • Exchange
  • NYXH Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • NYXH 261.1M
  • NKTR 247.9M
  • IPO Year
  • NYXH 2021
  • NKTR 1994
  • Fundamental
  • Price
  • NYXH $10.85
  • NKTR $0.89
  • Analyst Decision
  • NYXH Strong Buy
  • NKTR Strong Buy
  • Analyst Count
  • NYXH 5
  • NKTR 5
  • Target Price
  • NYXH $17.00
  • NKTR $4.50
  • AVG Volume (30 Days)
  • NYXH 64.9K
  • NKTR 1.5M
  • Earning Date
  • NYXH 03-13-2025
  • NKTR 03-03-2025
  • Dividend Yield
  • NYXH N/A
  • NKTR N/A
  • EPS Growth
  • NYXH N/A
  • NKTR N/A
  • EPS
  • NYXH N/A
  • NKTR N/A
  • Revenue
  • NYXH $5,668,079.00
  • NKTR $93,137,000.00
  • Revenue This Year
  • NYXH $22.93
  • NKTR $12.85
  • Revenue Next Year
  • NYXH $411.04
  • NKTR N/A
  • P/E Ratio
  • NYXH N/A
  • NKTR N/A
  • Revenue Growth
  • NYXH 32.65
  • NKTR 5.53
  • 52 Week Low
  • NYXH $4.27
  • NKTR $0.50
  • 52 Week High
  • NYXH $20.00
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • NYXH 77.88
  • NKTR 38.67
  • Support Level
  • NYXH $8.86
  • NKTR $0.88
  • Resistance Level
  • NYXH $10.08
  • NKTR $1.25
  • Average True Range (ATR)
  • NYXH 0.60
  • NKTR 0.09
  • MACD
  • NYXH 0.22
  • NKTR -0.01
  • Stochastic Oscillator
  • NYXH 84.81
  • NKTR 5.79

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: